Business Wire (Tue, 8:10AM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
399 people get ACOR articles and Market Currents by email alert.
Get email alerts on ACOR »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
Business Wire (Fri, 7:00AM)
-
Business Wire (May 15, 2013)
-
Business Wire (May 9, 2013)
-
Business Wire (May 6, 2013)
-
Business Wire (May 2, 2013)
-
Business Wire (Apr 25, 2013)
-
-
-
-
Business Wire (Apr 15, 2013)
-
-
-
Business Wire (Mar 20, 2013)
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
Bullish on Acorda: New Drug Looks PromisingZacks Investment Research • Tue, Jun 23, 2009
-
Acorda Pops on Good NewsZacks Investment Research • Thu, May 7, 2009
-
-
Acorda Down on FDA DelayZacks Investment Research • Tue, Mar 31, 2009
-
-
Acorda Therapeutics: Sell or Short?Martin Roth • Mon, Oct 1, 2007 -
Loeb's Third Point LLC Lowering Its Stake in AcordaLon Juricic • Fri, May 25, 2007 -
Activist Hedge Fund Seeks Sale of AcordaCentient Biotech Investor • Sun, Feb 25, 2007 -
Acorda Therapeutics Responds to Loeb's Sale SuggestionLon Juricic • Sun, Feb 25, 2007
-
Acorda Therapeutics: Loeb's Third Point Urges Sale of CompanyLon Juricic • Fri, Feb 23, 2007
-
Eye on Acorda TherapeuticsAnthony Payne • Tue, Feb 20, 2007 -
-
-
-
-
-
-
-
-
-
-
-
6 Liquid Small-Cap Healthcare Stocks Projected For Strong GrowthZetaKap • Thu, Aug 30, 2012
-
-
-
6 Analyst Backed Small Cap Biotech Stocks With Plenty Of Cash CashZetaKap • Fri, Aug 3, 2012
-
7 Fast Growing Small Cap Biotech Stocks With Analyst ConfidenceZetaKap • Fri, Jul 6, 2012
-
-
-
-
6 Small Cap Stocks With Plenty Of Cash On Hand And Strong Expected GrowthZetaKap • Thu, May 24, 2012
-
6 High-Growth Biotech Stocks Analysts Rate As BuysZetaKap • Fri, May 18, 2012
-
Acorda Therapeutics CEO Discusses Q3 2010 - Earnings Call TranscriptMon, Nov 1, 2010
-
Acorda Therapeutics, Inc. Q2 2010 Earnings Call TranscriptTue, Aug 3, 2010
-
Acorda Therapeutics, Inc. Q1 2010 Earnings Call TranscriptFri, Apr 30, 2010
-
Acorda Therapeutics Inc. Q4 2008 Earnings Call TranscriptTue, Feb 24, 2009
-
Acorda Therapeutics, Inc., Q3 2008 Earnings Call TranscriptTue, Nov 4, 2008
-
Acorda Therapeutics, Inc. Q2 2008 Earnings Call TranscriptFri, Sep 5, 2008
-
Acorda Therapeutics Inc. Q1 2008 Earnings Call TranscriptMon, May 5, 2008
-
Acorda Therapeutics Q3 2007 Earnings Call TranscriptTue, Nov 6, 2007
-
Business Wire (Fri, 7:00AM)
-
Business Wire (May 15, 2013)
-
Business Wire (May 9, 2013)
-
Business Wire (May 6, 2013)
-
Business Wire (May 2, 2013)
-
Business Wire (Apr 25, 2013)
-
at CNBC.com (Apr 15, 2013)
-
at CNBC.com (Apr 15, 2013)
-
Business Wire (Apr 15, 2013)
-
Business Wire (Mar 20, 2013)
-
Business Wire (Feb 25, 2013)
-
Business Wire (Feb 19, 2013)
-
Business Wire (Feb 14, 2013)
-
Business Wire (Feb 13, 2013)
ACOR vs. ETF Alternatives
Company Description
We are a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI), and other disorders of the nervous system. The first... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Monday, May 20, 12:31 PM Acorda Therapeutics (ACOR -1%) is issued a patent for Amprya entitled "Methods of Using Sustained Release Aminopyridine Compositions." This patent covers a range of dosage strengths, and is separate from 2 method of use patents issued in 2011 and 2013 that are set to expire in 2027 and 2026, respectively. The drug is approved in the United States as a treatment to improve walking in patients with multiple sclerosis. Comment! [Healthcare, On the Move]
- Thursday, May 2, 6:12 AM Acorda Therapeutics (ACOR): Q1 EPS of $0.09 misses by $0.11. Revenue of $71.9M misses by $8.81M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, May 2, 12:05 AM Notable earnings before Thursday’s open: ABMD, ACOR, ACT, AEE, ANR, ANSS, ARG, ARQL, ATK, AYR, BDBD, BDX, BEAM, BGCP, BZH, CAH, CEVA, CHD, CI, CME, CNP, CPN, CTRX, DIN, DNR, EL, ELNK, FIG, FLY, FNP, FWLT, GEL, GG, GIL, GM, GNRC, GOLD, HAR, HK, HSH, INCY, INGR, IP, IRDM, IT, ITT, K, LF, LQDT, LXP, MDC, MFC, MGI, MGM, MMC, MMP, MWW, NIHD, NNN, NUS, OCN, OGE, OXF, OZM, PCG, PPL, PWR, PXP, RGLD, RNO, SBH, SFY, SHPG, SNI, SPR, SRE, STRA, TEVA, VMC, VRX, WNR, WPX, WWE, XEL Comment! [Earnings]
- Wednesday, May 1, 5:30 PM Notable earnings before Thursday’s open: ABMD, ACOR, ACT, AEE, ANR, ANSS, ARG, ARQL, ATK, AYR, BDBD, BDX, BEAM, BGCP, BZH, CAH, CEVA, CHD, CI, CME, CNP, CPN, CTRX, DIN, DNR, EL, ELNK, FIG, FLY, FNP, FWLT, GEL, GG, GIL, GM, GNRC, GOLD, HAR, HK, HSH, INCY, INGR, IP, IRDM, IT, ITT, K, LF, LQDT, LXP, MDC, MFC, MGI, MGM, MMC, MMP, MWW, NIHD, NNN, NUS, OCN, OGE, OXF, OZM, PCG, PPL, PWR, PXP, RGLD, RNO, SBH, SFY, SHPG, SNI, SPR, SRE, STRA, TEVA, VMC, VRX, WNR, WPX, WWE, XEL Comment! [Earnings]
- Tuesday, April 16, 2:17 PM Acorda Therapeutics (ACOR +11.2%) rises for a second day after AMPYRA shows promise for post-stroke deficit patients. Heard on the conference call: 1) "What got us here [is] an adherence to analysis in science [and] we're not going to deviate from that" just to get into a Phase III trial. 2) An 18-20% improvement in the timed 25-foot walk speed "correlates very well with various measures of clinically meaningful improvement," but the comparison between the current study and the MS study "is not apples-to-apples." Comment! [Healthcare, On the Move]
-
Tuesday, April 16, 12:59 PM
Midday top 10 gainers: UNXL +16%. CNIT +15%. ANEN +15%. CHCI +14%. SYNM +13%. PNFP +12%. EVC +12%. ENPH +11%. NCQ +11%. ACOR +11%.
Midday top 10 losers: JAXB -33%. KEYN -15%. SRPT -12%. CPGI -10%. GENE -10%. TRIT -9%. CCXI -9%. MAGS -9%. ADAT -8%. GAI -8%. Comment! [On the Move] -
Monday, April 15, 12:50 PM
Midday top 10 gainers: MKTAY +143%. CNIT +21%. GENE +21%. THRX +18%. MCOX +17%. SGRP +14%. S +13%. STXS +10%. ACOR +9%. LIFE +8%.
Midday top 10 losers: UNTK -48%. GSS -19%. ASM -18%. DSCO -17%. HXM -16%. XPL -16%. NGD -16%. TGD -15%. BAA -14%. PZG -14%. Comment! [On the Move] - Monday, April 15, 8:24 AM Acorda Therapeutics (ACOR) says a proof-of-concept trial shows AMPYRA, the company's FDA approved walking treatment for multiple sclerosis, also improves walking in patients with post-stroke deficits. ACOR says once it has completed its analysis it will consult with the FDA on developing the drug for use by stroke survivors. Shares +8.6% premarket. Comment! [Healthcare, On the Move]
- Wednesday, February 13, 11:20 AM Acorda Therapeutics (ACOR +1.9%) hits new 52-week highs after it reported better-than-expected results for Q4. Revenue for the quarter came in at $81.5 million, beating the $78.90 million consensus. Additonally, the company says it plans to submit an NDA to the FDA for a diazepam nasal spray in 2013. Comment! [Healthcare, Earnings, On the Move]
- Wednesday, February 13, 6:09 AM Acorda Therapeutics (ACOR): Q4 EPS of $0.24 misses by $0.04. Revenue of $81.5M beats by $2.6M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Wednesday, October 31, 2012, 1:49 PM Acorda Therapeutics (ACOR +7.4%) trades up after its Q3 earnings beat estimates this morning. Sales of lead product Ampyra came in at $69M for the period, up 5% Y/Y, and above the Consensus expectations of $68M. The company also said that it is reaffirming its 2012 Ampyra net sales guidance of $255M - $275M. Comment! [Healthcare, Earnings, On the Move]
- Wednesday, October 31, 2012, 6:56 AM Acorda Therapeutics (ACOR): Q3 EPS of $0.38 beats by $0.14. Revenue of $77.4M (-16.8% Y/Y) beats by $2.2M. (PR) Comment! [Earnings, Healthcare]
- Tuesday, October 2, 2012, 10:39 AM Shares of Acorda Therapeutics (ACOR +3.7%) gain on heavy volume this morning following S&P's announcement late yesterday that it would be added to the S&P SmallCap 600 index. Comment! [Healthcare, On the Move]
- Monday, October 1, 2012, 5:43 PM PetSmart (PETM) +2.5% AH on news the stock will be added to the S&P 500 after the close on Oct. 4, replacing Sunoco (SUN) following the latter's buyout by ETP. Cabela's (CAB) will replace PETM in the S&P MidCap 400; Acorda Therapeutics (ACOR) will replace CAB in the S&P SmallCap 600. Comment! [Consumer, Energy, On the Move]
- Tuesday, July 31, 2012, 6:35 AM Acorda Therapeutics (ACOR): Q2 EPS of $0.27 in-line. Revenue of $75.7M (+15.9% Y/Y) beats by $3.1M. (PR) Comment! [Earnings, Healthcare]
- Thursday, May 3, 2012, 6:33 AM Acorda Therapeutics (ACOR): Q1 EPS of $0.36 beats by $0.09. Revenue of $71.2M (+16.2% Y/Y) in-line. (PR) Comment! [Earnings, Healthcare]